This transcript has been edited for clarity.
Robert A. Harrington, MD: Hi. I'm Bob Harrington from Stanford University, and I'm here in the Medscape booth on the floor of ACC22. It's certainly fantastic to be back at a live face-to-face meeting and not having to watch a Zoom screen all day. We wanted to take the opportunity to chat about some of the really hot topics at ACC22.
I'm really fortunate today to be joined by a colleague, Dr Jacqueline Tamis-Holland, who is a professor of medicine at the Icahn Medical School at Mount Sinai in New York City. For the purposes of this conversation, Dr Tamis-Holland was the vice chair of the recent ACC/AHA revascularization guidelines that came out at the end of December 2021. Those guidelines have updated many previous statements from the ACC and the AHA, and I thought this would be a good time to catch up on some of the key elements around that.
Dr Tamis-Holland, thanks for joining me here.
Jacqueline E. Tamis-Holland, MD: Thank you. I'm so happy to be here.
Harrington: Let's first talk about process. For the people who are unfamiliar with guidelines, let's let them know how these guidelines are constructed, and in particular for this one, because you had to bring together different disciplines to address the surgical issues, percutaneous issues, and medical issues.
Acute Coronary Syndrome
Unstable Angina
Acute Coronary Syndromes Clinical Practice Guidelines (ESC, 2020)
COMMENTARY
New Revascularization Guidelines: Key Points and Navigating Controversies
Robert A. Harrington, MD; Jacqueline E. Tamis-Holland, MD
DisclosuresApril 25, 2022
This transcript has been edited for clarity.
Robert A. Harrington, MD: Hi. I'm Bob Harrington from Stanford University, and I'm here in the Medscape booth on the floor of ACC22. It's certainly fantastic to be back at a live face-to-face meeting and not having to watch a Zoom screen all day. We wanted to take the opportunity to chat about some of the really hot topics at ACC22.
I'm really fortunate today to be joined by a colleague, Dr Jacqueline Tamis-Holland, who is a professor of medicine at the Icahn Medical School at Mount Sinai in New York City. For the purposes of this conversation, Dr Tamis-Holland was the vice chair of the recent ACC/AHA revascularization guidelines that came out at the end of December 2021. Those guidelines have updated many previous statements from the ACC and the AHA, and I thought this would be a good time to catch up on some of the key elements around that.
Dr Tamis-Holland, thanks for joining me here.
Jacqueline E. Tamis-Holland, MD: Thank you. I'm so happy to be here.
Harrington: Let's first talk about process. For the people who are unfamiliar with guidelines, let's let them know how these guidelines are constructed, and in particular for this one, because you had to bring together different disciplines to address the surgical issues, percutaneous issues, and medical issues.
© 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: New Revascularization Guidelines: Key Points and Navigating Controversies - Medscape - Apr 25, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Authors
Robert A. Harrington, MD
Arthur L. Bloomfield Professor; Chair, Department of Medicine, Stanford University; Chair, Department of Medicine, Stanford Medical Center, Stanford, California
Disclosure: Robert A. Harrington, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Element Science; MyoKardia; WebMD; SignalPath; American Heart Association; Stanford Healthcare; Knowledge2Practice
Received research grant from: Apple; CSL; Sanofi; AstraZeneca; Portola; Janssen; Bristol-Myers Squibb; Novartis
Received income in an amount equal to or greater than $250 from: Element Science; MyoKardia; WebMD; SignalPath; American Heart Association; Stanford Healthcare; Knowledge2Practice
Received grants for clinical research: American College of Cardiology; American Heart Association; National Heart, Lung, and Blood Institute, National Institute on Aging; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Johnson & Johnson; Eli Lilly; Merck; Novartis; Portola; Regado Biosciences; Sanofi; the Medicines Company
Jacqueline E. Tamis-Holland, MD
Professor of Medicine, Department of Cardiology, Icahn School of Medicine; Associate Director, Cardiac Catheterization Laboratory, Mount Sinai Morningside Hospital, New York, NY
Disclosure: Jacqueline E. Tamis-Holland, MD, has disclosed no relevant financial relationships.